Sandoz has an unwavering commitment to increasing patient access to high-quality, life-enhancing biosimilars. Sandoz is the global market leader and currently markets three biosimilars outside the US, each of which occupies the #1 biosimilar position in its respective category. Sandoz has a leading pipeline with several biosimilars across the various stages of development, including five programs in Phase III clinical trials/filing preparation.
The publication presents an analysis of the US market after the FDA officially approved the first US biosimilar – Zarxio (filgrastim-sndz.
January 25, 2016
Sandoz announced today that it has entered into an exclusive license agreement with Kyowa Hakko Kirin Co., Ltd for the distribution and promotion of its biosimilar rituximab....
Biosimilars: The Sandoz Way
Joerg Windisch talks about biosimilars development and manufacturing at Sandoz.
Biosimilar medicines offer physicians more choices at affordable prices thereby increasing patient access without increasing overall spending.Read more